LifeMD price target raised to $18 from $15 at BTIG

BTIG raised the firm’s price target on LifeMD (LFMD) to $18 from $15 and keeps a Buy rating on the shares. The firm states that sentiment among investors toward meeting the management team at it recent roadshow was generally positive as demand for obesity health services and GLP-1s remains very robust, while also noting that LifeMD is diversifying its business across new service line, the analyst tells investors in a research note. LifeMD appears to have a good relationship with both Lilly (LLY) and Novo Nordisk (NVO), and growth sounds steady, BTIG added.